Cellular senescence clearance (senolytics)
Yüth® contains compounds with senolytic activity — the ability to selectively eliminate senescent ('zombie') cells that accumulate with age and secrete pro-inflammatory SASP (senescence-associated secretory phenotype) factors that impair surrounding tissue function. Fisetin, a key senolytic flavonoid, reduces senescent cell burden in aging tissues, reducing the inflammatory milieu that drives age-related disease.
Autophagy enhancement and cellular rejuvenation
Multiple Yüth® components activate autophagy — the cellular self-cleaning process that removes damaged proteins and organelles. Spermidine (autophagy induction via eIF5A hypusination), urolithin A (mitophagy activation), and quercetin (mTOR inhibition) provide complementary autophagy activation across multiple cellular pathways, promoting cellular renewal and healthspan extension.
Mitochondrial health and biogenesis
Urolithin A specifically activates mitophagy (selective autophagy of dysfunctional mitochondria) and promotes mitochondrial biogenesis — increasing both the quality and quantity of mitochondria in aging cells. This is the primary mechanism behind urolithin A's documented improvements in muscle endurance and exercise capacity in older adults in RCTs.
Anti-aging and longevity pathway activation
The polyphenol combination in Yüth® activates multiple validated longevity pathways simultaneously — AMPK (cellular energy sensing), SIRT1 (longevity deacetylase), mTOR inhibition (anti-aging autophagy switch), and Nrf2 (antioxidant gene expression). This multi-pathway approach mirrors the mechanism of caloric restriction — the most robustly validated intervention for extending healthspan in model organisms.
Fisetin senolytic activity and SASP reduction
Fisetin selectively induces apoptosis in senescent cells by inhibiting anti-apoptotic BCL-2 family proteins (BCL-XL) that senescent cells over-express to resist normal cell death. By clearing senescent cells, fisetin reduces the SASP inflammatory milieu — a cocktail of cytokines (IL-6, IL-8, MMP-3) that accelerates aging in neighboring tissue. This mechanism is shared with the pharmaceutical senolytics dasatinib and quercetin, but with a more favorable safety profile.
Randomized, double-blind, placebo-controlled trial of urolithin A supplementation (500 mg/day) in 66 older adults for 4 months.
66 older adults (ages 65–90). 4-month RCT measuring muscle endurance and mitochondrial markers.
Urolithin A significantly improved muscle endurance (walking distance, grip strength), increased mitochondrial biomarkers, and activated gene expression signatures consistent with mitophagy and mitochondrial biogenesis vs. placebo. Well-tolerated. Supports urolithin A as a mitophagy activator for healthy aging.